期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿达木单抗在类风湿关节炎治疗中的应用 被引量：5

Adalimumab in the treatment of rheumatoid arthritis
原文传递
导出
摘要 生物制剂治疗风湿性疾病是近十年来风湿病诊治领域的重大突破和进展,首个全人源化肿瘤坏死因子(TNF)-α单克隆抗体——阿达木单抗(adalimumab)的问世,有效推进了临床类风湿关节炎治疗的进展。本文综述阿达木单抗在类风湿关节炎治疗中的应用。 Biological agents for the treatment of rheumatic diseases have made a major breakthrough over the past decade. Since the discovery of adalimumab, a tumor necrosis factor （TNF） -α inhibitor, the rheumatoid arthritis therapy has been made significant progress. This article reviews related progress in the treatment of rheumatoid arthritis with adalimumab.
作者 谢玉婷 汪年松
机构地区 上海交通大学附属第六人民医院肾脏风湿科
出处 《世界临床药物》 CAS 2012年第2期65-69,共5页 World Clinical Drug
关键词 阿达木单抗 肿瘤坏死因子α拮抗剂 类风湿关节炎 adalimumab tumor necrosis factor-α inhibitor rheumatoid arthritis
分类号 R593.22 [医药卫生—内科学] R977 [医药卫生—药品]
  • 相关文献

参考文献21

  • 1肿瘤坏死因子抑制剂作用机制的研究进展[J].中华风湿病学杂志,2011,15(3):216-216. 被引量：2
  • 2Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial [J]. Arthritis Rheum, 2003, 48 (1) : 35-45.
  • 3Weinblatt ME, Keystone EC, Furst DE, et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study [J]. Ann Rheum Dis, 2006, 65 (6) : 753-759.
  • 4Jamal S, Patra K, Keystone EC. Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis [J]. Clin Rheumatol, 2009, 28 (4) : 413-419.
  • 5Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J]. Arthritis Rheum, 2006, 54(1): 26-37.
  • 6Burmester GR, Mariette X, Montecuceo C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research inActive Rheumatoid Arthritis (ReAct) trial[J]. Ann Rheum Dis, 2007, 66 (6) : 732-739.
  • 7Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice [J]. Rheumatology (Oxford), 2007, 46(7): 1191-1199.
  • 8van der Heijde D, Landewe R, Keystone EC, et al. Adalimumab plus MTX prevents nearly all severe radiographic progression observed with methotrexate monotherapy in early, aggressive rheumatoid arthritis [J]. Arthritis Rheum, 2005, S 110.
  • 9Hetland ML, Christensen I J, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry[J]. Arthritis Rheum, 2010, 62 (1) : 22-32.
  • 10黄烽,张奉春,鲍春德,陶怡,古洁若,徐建华,朱平,徐沪济,张志毅,赵东宝,吴东海.阿达木单抗联合甲氨蝶呤治疗类风湿关节炎的多中心、随机、双盲、安慰剂对照临床研究[J].中华内科杂志,2009,48(11):916-921. 被引量：15

二级参考文献41

  • 1孙丽霞.类风湿性关节炎治疗药——阿达木单抗(adalimumab)[J].世界临床药物,2005,26(4):251-251. 被引量：4
  • 2刘晓光,张岩,白艳春,燕春山,李吉娜.类风湿性关节炎的治疗和护理体会[J].现代医药卫生,2007,23(11):1715-1716. 被引量：6
  • 3Zeng QY, Chen R, Darmawan J, et al. Rheumatic diseases in China. Arthritis Res Ther,2008,10 : R17.
  • 4Sangha O. Epidemiology of rheumatic diseases. Rheumatology (Oxford) ,2000,39 Suppl 2:3-12.
  • 5Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol, 1996,14:397-440.
  • 6Kwak HB, Jin HM, Ha H, et al. Tumor necrosis factor-alpha induces differentiation of human peripheral blood mononuclear cells into osteoclasts through the induction of p21 ( WAF1/Cipl ). Biochem Biophys Res Commun,2005,330 : 1080-1086.
  • 7Zou W, Hakim I, Tschoep K, et al. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoelast differentiation by an autocrine mechanism. J Cell Biochem,2001,83:70-83.
  • 8Zhang YH, Heulsmann A, Tondravi MM, et al. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem,2001, 276:563-568.
  • 9Kim HY, Lee SK, Song YW, et aL A randomized, double-blind, placebo-controlled, phase Ⅲ study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. APLAR J Rheumatol, 2007,10:9-16.
  • 10Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab ( a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy : a randomized, placebo-controlled, 52-week triM. Arthritis Rheum ,2004,50 : 1400-1411.

共引文献29

同被引文献15

引证文献5

二级引证文献20

世界临床药物
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部